Holen Sie sich die Stockscreener-App
11.88
1.25%
-0.15
Handel nachbörslich:
11.88
Schlusskurs vom Vortag:
$12.03
Offen:
$12.25
24-Stunden-Volumen:
1.17M
Relative Volume:
2.33
Marktkapitalisierung:
$629.25M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-4.6957
EPS:
-2.53
Netto-Cashflow:
$-82.68M
1W Leistung:
-13.98%
1M Leistung:
-8.62%
6M Leistung:
-14.53%
1J Leistung:
+181.52%
1-Tages-Spanne:
$11.84
$12.60
1-Wochen-Bereich:
$11.82
$14.72
52-Wochen-Spanne:
$3.77
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| STOK | 11.88 | 629.25M | 8.78M | -104.70M | -82.68M | -2.53 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
How To Trade (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 8.3%Here's Why - MarketBeat
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Lynx1 Capital Management LP's Strategic Acquisition in Stoke The - GuruFocus.com
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade - MSN
FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst - Defense World
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Wedbush Lifts Earnings Estimates for Stoke Therapeutics - MarketBeat
Research Analysts Offer Predictions for STOK FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for STOK FY2024 Earnings - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts - Simply Wall St
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues - Yahoo Finance
Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright - MarketBeat
Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study - TipRanks
Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1%Time to Sell? - MarketBeat
Stoke Therapeutics earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics (STOK) Q3 2024 Earnings: Revenue Surges to $4 - GuruFocus.com
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Business Wire
Vanguard Group Inc's Strategic Acquisition in Stoke Therapeutics Inc - GuruFocus.com
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Assenagon Asset Management S.A. Sells 155,723 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Skorpios Trust - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lessened by SG Americas Securities LLC - MarketBeat
Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $20.83 - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for STOK - MarketBeat
Is Stoke Therapeutics Inc (STOK) worth investing in despite its overvalued state? - US Post News
Stoke Therapeutics (NASDAQ:STOK) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat
Stoke Therapeutics Inc (STOK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Shares Gap UpWhat's Next? - MarketBeat
Stoke Therapeutics Inc’s Market Journey: Closing Strong at 11.84, Up 3.86 - The Dwinnex
TD Cowen upgrades Stoke Therapeutics Inc (STOK) rating to an Outperform - Knox Daily
Leerink Partners Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Millennium Management LLC Has $3.91 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Renaissance Technologies LLC Has $151,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday - MSN
Short Interest in Stoke Therapeutics, Inc. (NASDAQ:STOK) Declines By 19.9% - MarketBeat
Stoke Therapeutics assumed with an Outperform at Leerink - Yahoo Finance
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases - Yahoo Finance
Stoke Therapeutics Inc (STOK)’s stock chart: A technical perspective - US Post News
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownWhat's Next? - MarketBeat
Recent Insider Activity Suggests Potential Gains for Stoke Therapeutics Inc (STOK) - Knox Daily
STOK’s Market Whiplash: 133.46% YTD Rise, -20.00% Plunge in 30 Days - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Trading 3.4% HigherWhat's Next? - MarketBeat
10 Small Cap Stocks with High Potential - Insider Monkey
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):